An observational study in Ovarian Cancer, Endometrial Cancer and Cervical Cancers, sponsored by Medical University of Silesia. Completed at 1 site in Poland. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by Medical University of Silesia · Observational
Among 97 studies in Ovarian Neoplasms with a site in Poland — 20 open to participants now, 35 under way, 21 of them phase 3. Ovarian Neoplasms · Poland.
Among the 97 studies in Ovarian Neoplasms with a site in Poland, this one is the 7th largest by enrollment of the 11 observational ones, is one of 8 that started in 2022, is one of 11 observational ones, and was the 89th registered.
3,381 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
This study's enrollment of 324 is above the median of 200 across 616 observational studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →20 of the 97 studies in Ovarian Neoplasms with a site in Poland are open now, in 12 countries. Each count lists the studies.
Of the 606 Ovarian Neoplasms studies recruiting now, 443 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →97 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 8 started in 2022.
Median enrollment 334 across the 86 interventional studies, 500 across the 11 observational. Of the 59 that completed or were terminated, 34 (58%) have results posted.
85 of 97 have an industry lead sponsor. The 10 most frequent:
Medical University of Silesia is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Medical University of Silesia has 2 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
11 of the studies in Ovarian Neoplasms with a site in Poland that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05128825K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncA Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | 2026-12-01 |
Among the 97 studies in Ovarian Neoplasms with a site in Poland, from their registry updates:
The goal of this cross-section observational and questionary based study is to learn how geological cancer survivors perceive sexual health support given by health care professionals during diagnosis and treatment process.
The main question to be answered is:
Who, when and to what extend should discuss the sexual health issues
The participants will answer online survey questions about Sexual health issues and Sexual counselling during diagnosis, treatment and follow-up.
The main aim of the study is to verify who, from medical specialist, should discuss the sexual health issues in gynecological cancer survivors, when that discussion should take places and to what exited all sexual issues should be discusses.
The secondary end points are:
The study is a cross-section observation one. It is based on a survey containing questions regarding basic socioeconomical factors, treatment history, reproductive history, and those concerning the opinion who, when, to what extend and how should ask about sexual issues during therapy modalities planning, treatment and follow-up.
Women after completing a treatment irrespectively of its type (surgery, radiation, chemotherapy, immune check point inhibitors) will be eligible for the study. Those who are no more sexually active and currently have no sexual partner will also be included.
After collecting the date three main analysis will be conducted to answer the study questions.
The results will be used as a basic for further work on recommendation on sexual health counselling in gynecological malignancies.
Women diagnosed with ovarian, cervical, endometrial, vulvar and vaginal cancer after completion of treatment irrespectively of its type (surgery, CTH, RTH, immunotherapy)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Observational questionnaire-based study
Who should counsel patients with gynecological malignancies
A set of questions were asked to verify the hypothesis that specialist in gynecological oncology should inform about sexual issues during the treatment ant after its completion. Timing, frequency of counselling and patients' preferences for sexual information sources were established.
Time frame: At least 8 weeks post treatment completion
Gender of gynecological oncologist counselling the patient
A set of questions were ask to verify the hypothesis that in case of cancer choosing the specialist in gynecological oncology in not gender-based but knowledge and skills-based.
Time frame: At least 8 weeks post treatment completion
Returning to sexual activity defining as any sexual contact with a partner or solo masturbation
A set of question were asked to verify factors that might influence returning to sexual activity after treatment completion
Time frame: At least 8 weeks post treatment completion
Plan to share: Yes — All anonymized data will be available
Supporting information: Study protocol, Clinical study report
Time frame: 31.12.2025
Access criteria: On request
Ran from Jan 2022 to primary completion in Jan 2024, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Silesia →